New Edition,is a peptide of 36–43 amino acids

The amyloid beta 1-40 peptide, often abbreviated as Aβ(1-40) or beta-amyloid (1-40), is a significant subject of study in neuroscience, particularly within the context of Alzheimer's disease (AD). This 40-residue peptide is a naturally occurring fragment derived from the larger amyloid precursor protein (APP) through a process called proteolysis. While amyloid beta peptides in general are fragments made of 36-43 amino acids, the Aβ(1-40) variant is one of the two major C-terminal variants of the amyloid-beta peptide, alongside Aβ(1-42). Understanding the properties and behavior of amyloid beta 1-40 peptide is crucial for advancing our knowledge of AD pathogenesis and for developing potential therapeutic strategies.

The Role of Amyloid Beta 1-40 in Brain Health and Disease

Amyloid beta peptides are physiologically present in the brain, cerebrospinal fluid (CSF), and other bodily fluids. In healthy individuals, these peptides are typically cleared from the brain. However, in conditions like Alzheimer's disease, the balance between production and clearance is disrupted, leading to the accumulation of these amyloid beta peptides. The Aβ(1-40) form is generally considered less prone to aggregation than its Aβ(1-42) counterpart, but it still plays a role in the formation of amyloid plaques. These plaques are a hallmark pathological feature found in the brains of individuals with AD.

The accumulation of amyloid beta peptides, including amyloid beta 1-40, is strongly implicated in the pathogenesis of Alzheimer's disease. While Aβ(1-42) has often been highlighted for its potent aggregation capabilities and association with rapid neuronal degeneration, Aβ(1-40) is also a significant component of these pathological deposits. Research indicates that both Aβ(1-42) and Aβ(1-40) peptides can form interlaced amyloid fibrils, contributing to the overall plaque burden and neurotoxicity. Furthermore, amyloid beta peptide 1-40 is also associated with aged Down's Syndrome, highlighting its broader relevance in neurodegenerative processes.

Research Applications and Catalog Peptides

The availability of amyloid beta 1-40 peptide as a single catalog peptide is vital for researchers investigating AD. These catalog peptides are synthesized to high-quality standards, ensuring their purity and consistency for experimental use. For instance, Beta-Amyloid (1-40), TFA and High quality recombinant Beta-Amyloid (1-40), HFIP are commonly used reagents in laboratories. These preparations, often with a purity exceeding 97%, allow scientists to study the aggregation properties, interactions with other molecules, and potential therapeutic interventions related to amyloid beta 1-40.

Researchers utilize these peptides in various experimental setups, including those examining amyloid beta peptide aggregation. Understanding how Aβ(1-40) aggregates and forms structures like senile plaque amyloid is a key area of investigation. Techniques may involve using Beta-Amyloid (1-40) Scrambled HFIP treated peptide as a control or to investigate specific structural aspects. The amyloid beta 1-40 peptide amino acid sequence is well-defined, allowing for precise structural and functional analyses.

The Significance of Aβ(1-40) Variants and Related Research

While Aβ(1-40) is a primary focus, understanding its relationship with other amyloid beta peptides is also important. For example, (Gln22)β-Amyloid (1-40) human represents a specific variant that may be studied for its unique properties. The distinction between Aβ(1-40) and Aβ(1-42) is critical, as their differing aggregation propensities contribute to the complex landscape of AD pathology. Studies have explored peptides that specifically bind to Aβ(1-40), aiming to develop targeted therapies.

The role of amyloid beta 1-40 peptide extends beyond plaque formation. Research has also identified enzymes, such as a new brain metalloendopeptidase, that can degrade the Alzheimer beta-amyloid 1-40 peptide, producing soluble fragments without apparent neurotoxic effects. This suggests potential avenues for therapeutic development focused on enhancing the clearance of these peptides.

In summary, the amyloid beta 1-40 peptide is a critical player in the complex pathology of Alzheimer's disease. As a fundamental component of amyloid plaques, its aggregation and interaction with other amyloid beta peptides contribute to neurodegeneration. The availability of high-quality amyloid beta 1-40 peptide as catalog peptides empowers researchers to delve deeper into its mechanisms,